Skip to main content

Table 2 Subgroup analysis of odds ratio (OR) of second cancers associated with cisplatin chemotherapy

From: Risk of second primary cancers in cancer patients treated with cisplatin: a systematic review and meta-analysis of randomized studies

Group

No. of trials

Cisplatin

Non-cisplatin

I2(%)

OR (95%CI)

P

No. of events

No. of patients

No. of events

No. of patients

OR

Interaction

Type of control

0.93

 Non-platinum

20

48

2856

40

2395

29

0.94 [0.60, 1.45]

0.77

 

 Other platinum

8

27

1077

28

1075

0

0.97 [0.56, 1.66]

0.90

 

Total cisplatin dose(mg/m2)

0.85

 ≤ 300

16

50

2461

41

1946

0

0.94 [0.61, 1.46]

0.80

 

 > 300

11

22

1323

26

1389

43

0.88 [0.50, 1.56]

0.66

 

Follow-up time(months)

0.77

 ≤ 60

18

40

2221

39

2203

4

0.99 [0.63, 1.56]

0.97

 

 > 60

10

35

1712

29

1267

30

0.89 [0.53, 1.50]

0.67

 

Mode of treatment

0.78

 Chemotherapy alone

19

30

2187

34

2247

19

0.90 [0.55, 1.48]

0.68

 

 Chemotherapy and radiotherapy

9

45

1746

34

1223

5

0.99 [0.62, 1.59]

0.98

 

Mode of comparison

0.40

 Un-confounded

16

53

2602

51

2228

28

0.88 [0.59, 1.32]

0.54

 

 Confounded

13

22

1331

18

1318

0

1.21 [0.65, 2.28]

0.54

 

Treatment setting

0.50

 Adjuvant

20

61

2747

56

2252

0

0.90 [0.62, 1.31]

0.65

 

 Metastasis

8

14

1186

12

1218

0

1.18 [0.59, 2.37]

0.58

Â